Prescribing for OA patients: new guide
The International NSAID Consensus Group, which developed the guidelines, said patients at risk of GI and cardiovascular (CV) events should have preventive strategies in place, such as inclusion of the lowest effective dose of NSAID, co-therapy with a gastroprotective drug, or the use of a COX-2 selective agent to optimise treatment outcomes.
However, many OA patients requiring NSAID therapy are not being treated according to their GI risk profile, the experts said.
The group has updated its 2008 statement, taking in the most recent evidence to address ongoing issues for primary care physicians in how to prescribe for patients with OA.
For the first time the guideline covers upper versus lower GI risk of COX-2 selective and non-selective NSAID (ns-NSAID) compounds.
It also addresses the GI and CV interaction these drugs have with low-dose aspirin, an area for which, until now, there was a lack of evidence.
For patients with both